Dr. Golnaz Moazami, MD

Dr. Moazami practices at New Hyde Park Endoscopy in Lake Success, New York.

Dr. Moazami's NPI, 1427075407, was assigned on July 16, 2006. Dr. Moazami graduated from Columbia University Vagelos College of Physicians and Surgeons in 1991. Dr. Moazami holds New York license 203828.

Dr. Moazami's primary practice is New Hyde Park Endoscopy, at 1991 Marcus Avenue, Lake Success, NY 11042. The practice phone is (317) 796-7565.

Dr. Moazami's primary practice is New Hyde Park Endoscopy in Lake Success, New York. Dr. Moazami is also affiliated with North Shore University Hospital. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Moazami to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moazami practices, 6 sites in all. Vendor and product names are available with a free account.

Neuro-ophthalmology is Dr. Moazami's primary specialty in the NPI Registry, under taxonomy code 207WX0109X. Dr. Moazami is licensed in New York.

CMS data shows 7,500 Medicare services from Dr. Moazami across 14 procedure codes in 2024, for 1,464 Medicare patients. Medicare paid $401,165 for them. Every service was in an office.

CMS counts 1,464 Medicare patients who saw Dr. Moazami in 2024. The largest group is 75 to 84, with 658 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.03, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Moazami's median patient age at 62, with 65% women.

In 2024, Dr. Moazami wrote 1,724 Medicare Part D claims for 435 patients. 57% of them were for generic drugs. CMS names the drug for 1,570 of them, across 28 drugs with 11 or more claims each, at $306,371 in total drug cost. In 2023, CMS named 1,715 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 0 out of 100 for Dr. Moazami for performance year 2024, reported individually. Dr. Moazami accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Moazami, published from 2019 to 2024. 2021 was the busiest year, with 2. The most frequent topics are Glioblastoma, Tomography, Optical Coherence and Brain Neoplasms. Dr. Moazami has published most often in J Neuroophthalmol. Dr. Moazami's most frequent co-authors are Dan Ang Gong, MD, Sigmund H. Hsu, MD and Marian S. Macsai, MD.

Dmand AI links Dr. Moazami to 3 clinical trials, 2 of them phase 3 studies. Conditions studied include Graves Ophthalmopathy, Optic Neuropathy, Ischemic and Pseudotumor Cerebri.

CMS Open Payments shows 16 general payments to Dr. Moazami from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 53% of the total. Shire North American Group Inc paid the most, $286. It also lists 11 research payments totaling $11,912 in 2016.

Dr. Moazami graduated from Columbia University Vagelos College of Physicians and Surgeons in 1991.